Disclaimer & Privacy

Privacy Policy

The only personal information that we collect from this website is the information that you voluntarily supply on our Contact Us section and the Email Alert Sign-up Forms. We use this personal information to respond to your request and, unless with your consent or as required by law, do not disclose your personal information outside Skinvisible. This personal information is kept on a database only as long as we need the information to respond to you. We take reasonable steps to safeguard your personal information and use our best efforts to ensure that persons who work with us to create and update this website agree to protect your personal information in the same manner.

Stock Information

The stock information are provided by Stockgroup Media Inc and ComStock, Inc, a division of Interactive Data Corp. and are subject to their terms of use. Corporate and Financial Data is provided by CoreData. Data and information is provided for informational purposes only, and is not intended for trading purposes. Stockgroup and Skinvisible shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Data is delayed 20 minutes for NYSE & AMEX and delayed 15 minutes for all other exchanges.

Latest News:

December 4, 2012
Skinvisible Granted US Patent for Topical Drug Delivery Technology - Invisicare® Patent Protection Extends to Year 2029

November 27, 2012
Skinvisible Granted US Patent for Stabilizing Retinoids - Intellectual Property Portfolio Strengthens

June 28, 2012
Skinvisible's Hand Sanitizer Kills "Super Bug" MRSA and E. coli For Up to 4 Hours - Studies Confirm One Application of DermSafe As An Effective Long-Lasting Hand Sanitizer

April 12, 2012
Skinvisible Licensee Increases US Sales for Women's Health Product Made with Invisicare - ProCort® Distribution Expands to Puerto Rico

March 7, 2012
Skinvisible Granted US Sunscreen Patent for UVA Absorber - Broad Spectrum UVA / UVB Sunscreens with Invisicare Offer Eight Hours of Photostability

February 23, 2012
Skinvisible Formulation Submitted to European Union for Orphan Drug Designation - Invisicare Formulation for Netherton Syndrome Under Review

CLICK HERE TO READ ALL NEWS RELEASES